XML 220 R38.htm IDEA: XBRL DOCUMENT v3.22.4
Stock-Based Compensation (Tables)
 12 Months Ended
Dec. 31, 2022
Share-Based Payment Arrangement [Abstract]  
Schedule of Share-Based Compensation Expense
The following table summarizes the stock-based compensation expense recognized under all of the Company’s stock plans in 2022, 2021, and 2020, and associated with the issuance of restricted shares of common stock and vesting of stock options that are included in general and administrative expenses in the accompanying consolidated statements of income recognized (in thousands):
Years ended December 31,
20222021            2020
Stock options$3,792 $2,480 $1,763 
Restricted stock awards12,309 4,265 1,620 
Total share-based compensation expense$16,101 $6,745 $3,383 
Schedule of Stock Option Transactions Under Stock Option Plans
The Company’s outstanding stock options consisted of the following:
SharesWeighted-Average
Exercise Price		Weighted-Average
Remaining
Contractual
Term
(Years)		Aggregate
Intrinsic
Value
(in millions)
Options outstanding at January 1, 2022813,965 $22.74 3.20$41.6 
Options granted87,488 51.21 — — 
Options exercised(41,603)17.81 — 1.0 
Options canceled, forfeited or expired— — — — 
Options outstanding at December 31, 2022859,850 $25.88 2.19$10.3 
Options exercisable at December 31, 2022734,027 $17.32 1.69$10.0 
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions During the year ended December 31, 2022, the Company granted 0.1 million stock options to certain ApolloMed employees and board members with exercise price ranging from $41.59-$53.01. The weighted-average grant-date fair value of options granted during the years ended December 31, 2022, 2021, and 2020, was $22.32, $32.63, and $9.89, respectively. The options granted during the year ended December 31, 2022 were recognized at fair value, as determined using the Black-Scholes option pricing model as follows:
December 31, 2022
Expected term
1.50 years - 2.25 years
Expected volatility
71.47% - 82.05%
Risk-free interest rate
1.02% - 2.47%
Market value of common stock
$17.47-$23.42
Share-based Payment Arrangement, Restricted Stock Activity
The Company’s unvested restricted stock award activity for the year ended December 31, 2022 consisted of the following:

Restricted Stock AwardsPerformance Based Restricted Stock Awards
Number of
Shares		Weighted Average
Grant-Date Fair Value		Number of
Shares		Weighted Average
Grant-Date Fair Value
Unvested as of January 1, 2022541,507$37.84$— $0.00
Granted 253,42941.07327,55242.12
Vested(244,475)35.28(29,289)50.69
Forfeited(10,829)33.42(8,628)45.80
Unvested as of December 31, 2022539,632$72.58289,635$41.14
Schedule of Outstanding Warrants The Company’s warrants activity consisted of the following:
SharesWeighted-Average
Exercise
Price		Weighted-Average
Remaining
Contractual
Term
(Years)		Aggregate
Intrinsic
Value
(in millions)
Warrants outstanding at January 1, 20221,001,740 $10.49 0.9463.1 
Warrants granted— — — — 
Warrants exercised(947,174)10.49 — 21.1 
Warrants forfeited(54,566)10.49 — — 
Warrants outstanding at December 31, 2022— $— — $—